文献速递胸部肿瘤

美国放射学会适用标准:局限期小细胞肺癌的放射治疗2020

American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020.
PubMed 文献 · J Thorac Oncol · 2020-11-06

美国放射学会胸部适用标准委员会针对局限期小细胞肺癌(LS-SCLC)的治疗争议,基于证据和改良德尔菲法制定共识指南。推荐不可切除LS-SCLC患者接受同步化放疗(每日一次或两次),医学不可手术的T1-T2N0患者可选择同步化放疗或立体定向体部放疗后辅助化疗,并继续推荐化放疗后预防性颅脑照射;海马保护预防性颅脑照射和PD-1/PD-L1免疫治疗不可常规临床试验外使用。

要点

  • 不可切除LS-SCLC推荐同步化疗联合每日一次或两次放疗。
  • 医学不可手术T1-T2N0 LS-SCLC可选同步化放疗或SBRT后辅助化疗。
  • 化放疗后继续推荐预防性颅脑照射;海马保护PCI和免疫治疗不可常规临床试验外使用。

核心结论

  • 美国放射学会胸部适用标准委员会针对LS-SCLC制定了多项共识推荐,旨在为多学科诊疗和临床试验提供基础。

研究设计与样本

  • 基于证据的指南,由多学科专家小组审查分析当前证据,应用改良德尔菲共识方法对推荐治疗适宜性进行评分,共识定义为评分与小组中位数相差不超过3分,经执行委员会审查和公众评议后定稿。

主要发现

  • 强烈共识认为不可切除LS-SCLC患者应接受同步化疗联合每日一次或两次放疗。
  • 对于医学不可手术的T1-T2N0 LS-SCLC,同步化放疗或立体定向体部放疗后辅助化疗均为合理选择。
  • 小组继续推荐化放疗有效后行全脑预防性颅脑照射。
  • 小组同意海马保护预防性颅脑照射和PD-1/PD-L1导向免疫治疗目前不应在临床试验外常规使用。

关键数值与推荐

  • 共识定义为评分与小组中位数相差不超过3分。
  • 不可切除LS-SCLC:同步化疗联合放疗(每日一次或两次)。
  • 医学不可手术T1-T2N0 LS-SCLC:同步化放疗或SBRT后辅助化疗。
  • 化放疗后推荐全脑预防性颅脑照射。
  • 海马保护PCI和PD-1/PD-L1免疫治疗不可常规临床试验外使用。

临床怎么用

  • 临床实践中,对不可切除LS-SCLC应优先采用同步化放疗;对医学不可手术的早期T1-T2N0患者可考虑SBRT后辅助化疗。
  • 化放疗后应评估并推荐全脑预防性颅脑照射;海马保护PCI和免疫治疗仅建议在临床试验中使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Combined modality therapy with concurrent chemotherapy and radiation has long been the standard of care for limited-stage SCLC (LS-SCLC). However, there is controversy over best combined modality practices for LS-SCLC. To address these controversies, the American Radium Society (ARS) Thoracic Appropriate Use Criteria (AUC) Committee have developed updated consensus guidelines for the treatment of LS-SCLC. METHODS: The ARS AUC are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for LS-SCLC. Agreement or consensus was defined as less than or equal to 3 rating points from the panel median. The consensus ratings and recommendations were then vetted by the ARS Executive Committee and subject to public comment before finalization. RESULTS: The ARS Thoracic AUC committee developed multiple consensus recommendations for LS-SCLC. There was strong consensus that patients with unresectable LS-SCLC should receive concurrent chemotherapy with radiation delivered either once or twice daily. For medically inoperable T1-T2N0 LS-SCLC, either concurrent chemoradiation or stereotactic body radiation followed by adjuvant chemotherapy is a reasonable treatment option. The panel continues to recommend whole-brain prophylactic cranial irradiation after response to chemoradiation for LS-SCLC. There was panel agreement that prophylactic cranial irradiation with hippocampal avoidance and programmed cell death protein-1/programmed death-ligand 1-directed immune therapy should not be routinely administered outside the context of clinical trials at this time. CONCLUSIONS: The ARS Thoracic AUC Committee provide consensus recommendations for LS-SCLC that aim to provide a groundwork for multidisciplinary care and clinical trials.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Chun SG, Simone CB, Amini A, et al. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. J Thorac Oncol. 2020. PMID: 33166720. doi:10.1016/j.jtho.2020.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。